Male birth control pill enters human testing

NCT ID NCT06542237

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new daily pill called YCT-529 for male contraception. It involves 88 healthy men who have decided not to have children. The pill is taken for 28, 90, or 180 days to check its safety, side effects, and how well it works. This is an early step toward giving men a daily birth control option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

YCT-529 (a daily oral pill for male contraception)

What this could lead to

If successful, this could lead to a new, non-hormonal daily birth control pill for men, giving couples more options.

What could go wrong

This is an early-phase trial with only 88 men, so it may not prove safe or effective enough. Side effects or lack of reliable contraception are possible risks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALE CONTRACEPTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple endocrine neoplasia type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • New Zealand Clinical Research (NZCR)

    RECRUITING

    Grafton, Auckland, 1010, New Zealand

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••